Lokelma
Payments companies reported to CMS as associated with Lokelma. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lokelma, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lokelma
These are the largest totals companies reported as associated with Lokelma. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mark Haigney | Bethesda, MD | Cardiovascular Disease | $103,250.00 |
| Rakesh Gulati | Philadelphia, PA | Nephrology (Internal Medicine) | $97,031.61 |
| Daniel Gray | Rochester, NY | Nephrology (Internal Medicine) | $87,500.00 |
| Anthony Blalock | Lafayette, LA | Nephrology (Internal Medicine) | $74,817.63 |
| Jose Morfin | Sacramento, CA | Nephrology (Internal Medicine) | $60,967.25 |
| Derek Larson | Creve Coeur, MO | Nephrology (Internal Medicine) | $55,167.01 |
| Ashte Collins | Washington, DC | Nephrology (Internal Medicine) | $51,703.72 |
| Christian Mende | La Jolla, CA | $48,403.89 | |
| Gregory Greenwood | Winston-Salem, NC | Nephrology (Internal Medicine) | $41,728.74 |
| Katherine Kwon | Saint Joseph, MI | Nephrology (Internal Medicine) | $39,665.55 |
Prescribed Lokelma?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.